Chronic Hepatitis News

The carriage of virulence factors in the commensal gut microbiota was associated with mortality in patients with alcoholic hepatitis, according to research presented at The Digital International Liver Congress.

Direct-acting antivirals first received approval for use in adults with hepatitis C in 2013. They were approved for use in children several years later, in 2017.

The COVID-19 pandemic has had “a tremendously negative impact” on efforts to eliminate hepatitis C, according to Ricardo Franco, MD.

Direct-acting antivirals for hepatitis C have not only led to a cure for the virus — they’ve also changed the paradigm in liver transplantation. This includes the transplantation of HCV-positive organs into HCV-negative recipients.

Treatment with direct-acting antivirals was associated with decreased mortality among a sample of more than 50,000 Medicare beneficiaries with hepatitis C virus, regardless of the presence of cirrhosis, according to data published in JAMA Network Open.

Primary care physicians do not realize how low the rate of adult hepatitis B vaccination is in the United States, according to a small survey.

In this exclusive video, Nancy S. Reau, MD, section chief of hepatology and associate director of organ transplantation at Rush University Medical Center, discusses some important aspects of treating liver diseases during the COVID-19 pandemic.

In this exclusive video, Nancy S. Reau, MD, section chief of hepatology and associate director of organ transplantation at Rush University Medical Center, discusses the lasting impacts of COVID-19 on hepatology practice.

In the United States, more than 80% of privately insured people with chronic hepatitis B infection remain undiagnosed, according to a recent study.

SVR, which has been challenged in regard to its association with clinical outcomes, has been confirmed as a prognosis-altering endpoint in patients with hepatitis C virus, according to findings published in Clinical Infectious Diseases.